TriSalus Life Sciences and the University of Colorado Anschutz Medical Campus entered a strategic research collaboration to advance research of immuno-oncology treatments for patients with liver and pancreatic tumors.
Over the next three years, TriSalus will collaborate with the University of Colorado Anschutz Medical Campus on studies using TriSalus’ proprietary Pressure-Enabled Drug Delivery (PEDD) method for the administration of an investigational toll-like receptor 9 (TLR9) agonist, SD-101.
TriSalus’ platform consists of an investigational immunotherapy, SD-101, that aims to reactivate the immune system within these organs for targeted tumor killing, and the PEDD method, which modulates pressure and flow within blood vessels to improve therapy uptake and tumor response.
CU Innovations has led the establishment of the business relationship while the CU Anschutz research team will focus on creating clinical research to advance TriSalus’ approach.
